Orchard Therapeutics (Orchard Therapeutics) Change In Receivables : $15.14 Mil (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Orchard Therapeutics Change In Receivables?

Orchard Therapeutics's change in receivables for the quarter that ended in Sep. 2023 was $1.70 Mil. It means Orchard Therapeutics's Accounts Receivable declined by $1.70 Mil from Jun. 2023 to Sep. 2023 .

Orchard Therapeutics's change in receivables for the fiscal year that ended in Dec. 2022 was $15.15 Mil. It means Orchard Therapeutics's Accounts Receivable declined by $15.15 Mil from Dec. 2021 to Dec. 2022 .

Orchard Therapeutics's Accounts Receivable for the quarter that ended in Sep. 2023 was $6.19 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Orchard Therapeutics's Days Sales Outstanding for the three months ended in Sep. 2023 was 89.58.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Orchard Therapeutics's liquidation value for the three months ended in Sep. 2023 was $11.36 Mil.

Orchard Therapeutics Change In Receivables Historical Data

The historical data trend for Orchard Therapeutics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchard Therapeutics Change In Receivables Chart

Orchard Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-11.01

-16.85

12.26

-14.54

15.15

Orchard Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Change In Receivables	Get a 7-Day Free Trial															-13.65	18.51	7.83	-12.89	1.70

Orchard Therapeutics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.14 Mil.

Orchard Therapeutics (NAS:ORTX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Orchard Therapeutics's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	6.187	/	6.302	*	91
=	89.58

2. In Ben Graham's calculation of liquidation value, Orchard Therapeutics's accounts receivable are only considered to be worth 75% of book value:

Orchard Therapeutics's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	125.413	-	122.008	+	0.75 * 6.187	+	0.5 * 6.638
=	11.36

Orchard Therapeutics Change In Receivables Related Terms

Thank you for viewing the detailed overview of Orchard Therapeutics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Orchard Therapeutics (Orchard Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchard Therapeutics PLC (NAS:ORTX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

OT10:Germany

Address

245 Hammersmith Road, London, GBR, W6 8PW

Website

https://www.orchard-tx.com

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.

Executives

Bobby Gaspar	director, officer: See Remarks	ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Steven Altschuler	director	MEAD JOHNSON NUTRITION COMPANY, 2701 PATRIOT BLVD, GLENVIEW IL 60026
Jon Ellis	director	ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
Plc Glaxosmithkline	director, 10 percent owner	980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS
Marc Dunoyer	director	ORCHARD THERAPEUTICS PLC, 108 CANNON STREET, LONDON X0 EC4N 6EU
John T Curnutte	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Rowland Charles A Jr	director	3338 LANCASHIRE RD, FURLONG PA 18925
Mark Rothera	director, officer: See Remarks	C/O AEGERION PHARMACEUTICALS, INC., 101 MAIN STREET, SUITE 1850, CAMBRIDGE MA 02142
James A Geraghty	director	C/O IDERA PHARMACEUTICALS, INC., 167 SIDNEY STREET, CAMBRIDGE MA 02139
Alicia Secor	director	33 HAYDEN AVE., LEXINGTON MA 02421